Helixgate

Helixgate

Uncategorized

Engineering macrophage-targeted trispecific immune cell engagers for tumor immunotherapy

Published

on

Nature Biotechnology, Published online: 30 March 2026; doi:10.1038/s41587-026-03104-5

Immune cell engagers (ICEs) have emerged as a promising strategy for cancer immunotherapy, but their efficacy in solid tumors remains limited, partly as a result of the difficulty of coordinating activating and inhibitory signals within the same immune cell. Here, we report a logic-gated cis-targeting strategy that enables ICEs to coordinate activating and inhibitory signals within macrophages, thereby enhancing tumor clearance in mouse models of solid cancers.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: States looking to regulate use of chatbots

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company. 

Continue to STAT+ to read the full story…

Read More

Published

on

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company. 

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

ARPA-H selects three teams in $100M effort to repair and regrow ailing joints

ARPA-H selects three teams in $100M effort to repair and regrow ailing joints

Published

on

Three academic centers believe they may have discovered new ways to heal aging joints. Now the federal government is funding clinical trials to test these experimental regenerative medicines in osteoarthritis.
Teams from Duke University, the …​ ​Read More

Continue Reading

Uncategorized

Terns sold to Merck for 13% lower than pharma’s initial offer because of clinical data

Published

on

Although Merck and Terns Pharmaceuticals are part of biotech’s M&A surge, the $6.7 billion deal didn’t nearly play out the way either anticipated.

Merck decided to significantly lower its offer for the …

Continue Reading
Advertisement

Trending